Navigation Links
Congresso ESH 2013, dallo studio SEVITENSION nuove evidenze sull'efficacia della combinazione fissa olmesartan/amlodipina vs. perindopril/amlodipina nel controllo della pressione arteriosa centrale
Date:6/25/2013

MILANO, June 25, 2013 /PRNewswire/ --

Nel corso del 23° Congresso della Società Europea di Ipertensione sono stati presentati gli ultimi dati dello studio SEVITENSION, che mostrano l'efficacia superiore della combinazione fissa olmesartan/amlodipina rispetto alla combinazione perindopril/amlodipina nel controllo della pressione arteriosa centrale. SEVITENSION prende le mosse dai risultati del precedente studio CAFÉ-Conduit Artery Function Evaluation (parte dello studio ASCOT), che aveva mostrato come i trattamenti in combinazione fissa abbiano effetti differenti sulla pressione arteriosa centrale.

"Queste evidenze - ha dichiarato Luis Ruilope, direttore dell'Unità Antipertensiva dell'Ospedale 12 Ottobre di Madrid e coordinatore dello studio Sevitension - potrebbero spiegare la differenza dei risultati clinici fra i due gruppi dello studio ASCOT e fornire utili indicazioni per aiutare i medici a scegliere la miglior opzione di trattamento per gestire in maniera più efficace e conveniente l'ipertensione, proteggendo i pazienti dal rischio cardiovascolare. L'ambizione è quella di raggiungere l'obiettivo di controllare adeguatamente la pressione arteriosa nel 70% dei pazienti entro il 2015".

Gli inibitori dell'enzima di conversione dell'angiotensina (ACE-I) agiscono bloccando l'enzima che trasforma l'angiotensina I in angiotensina II, mentre gli ARB agiscono bloccando il recettore dell'angiotensina II, offrendo peraltro il vantaggio di minori effetti collaterali rispetto agli ACE-I, in particolare la tosse.

Daiichi Sankyo continua il proprio impegno nell'ipertensione e nello sviluppo dell'olmesartan. Lo studio SEVITENSION si è concentrato proprio sulla valutazione della combinazione fissa olmesartan/amlodipina.

Lo studio SEVITENSION ha analizzato la combinazione di 40 mg di
'/>"/>

SOURCE Daiichi Sankyo Europe GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Online Course Helps Employers Comply with OSHA’s Dec. 1, 2013, GHS Training Deadline
2. MedZilla.com Launches New Site Design for 2013, Slick New Interface Impresses
3. VIASPACE Chairman and CEO Attend EUEC 2013, Giant King Grass Prominently Featured in Convention Exhibit Hall
4. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets
5. Retraction of Press Release Dated March 7, 2013, Regarding Recipient of Alumni Award from Johns Hopkins University
6. CANVUS Design Studio Specializes in Graphic Design and Commercials
7. Accelrys Materials Studio Release 6.1 Speeds Innovation with Enterprise Capabilities
8. Temple Run Gamers Have a New IOS Game To Play, Dream Bot Studios Explains
9. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
10. Winding River Productions Announces High-End Studio Enhancements Including SCORM-Compliant e-Learning Media Development and On-Location Data and Media Capture Platforms
11. Il Ministero della sanità canadese ha concesso le indicazioni sulla salute rivendicate da cinque formulazioni probiotiche di Lallemand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The 2015 Market ... study on the current state of the global Propanol market with a focus on ... BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... HUYA Bioscience International, a leader in globalizing ... the Shenzhen Polytechnic School of Applied Chemistry and Biotechnology ... in accelerating the development of novel drugs, discovered from ... The agreement provides HUYA with access to and ...
... NephroGenex, Inc., a privately held drug development company, ... the FDA on the design of a new Phase ... nephropathy patients.  This Subpart H program uses a novel ... (SCr), and provides for an accelerated regulatory pathway to ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a ... extracellular matrix for the diabetes, cancer, dermatology and ... third quarter of 2011 and discussed recent business progress. ... past few months highlight the progress at Halozyme on ...
Cached Biology Technology:HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology 2HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology 3NephroGenex Reaches Agreement with the FDA on a Subpart H Phase 3 Program for Pyridorin™ 2Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2011 Financial Results 7
(Date:7/9/2015)... July 07, 2015 ... addition of the "Biometrics for Banking; Market ... report to their offering. The ... to this growth and the forecast is that ... revenue for companies involved in delivering biometric systems ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... the battle against AIDS and a major development in the ... protein that prevents the virus from entering cells. This protein ... that protects cells from viruses, except the man-made version does ... needed to inhibit AIDS. This discovery was published in the ...
... Reducing Emissions from Deforestation and Forest Degradation ... that aims to financially compensate landowners and stewards ... as promoting forest conservation, sustainable forest management and ... and implemented correctly, REDD+ has the potential to ...
... RIVERSIDE, Calif. What are transposable elements, what role do ... they comprise? Is there an explanation for the genetic diversity ... spotted? What is the genetic basis for this spotted trait? ... a free public lecture at 6 p.m., Thursday, April 14, at ...
Cached Biology News:Intelligent design: Engineered protein fragment blocks the AIDS virus from entering cells 2REDD+, Technical, Socioeconomic and Political Dimensions 2REDD+, Technical, Socioeconomic and Political Dimensions 3Teaching old genomes new tricks 2
...
Anti-MMP-7, aminoterminal end active enzyme; rabbit host...
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: